Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 15/20 | 0.70 |
| ▸ | KIT | P10721 | 10/20 | 0.70 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.70 |
| ▸ | AURKA | O14965 | 3/20 | 0.67 |
| ▸ | JAK2 | O60674 | 2/20 | 0.67 |
| ▸ | AXL | P30530 | 2/20 | 0.61 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087568 | 0.92 | FLT3 (0.70) | FLT3KITIRAK4AURKAJAK2 | |
| SCHEMBL2088928 | 0.92 | FLT3 (0.70) | FLT3KITIRAK4AURKAJAK2 | |
| SCHEMBL2088002 | 0.86 | FLT3 (0.79) | FLT3KITIRAK4AURKAJAK2 | |
| SCHEMBL4038190 | 0.85 | FLT3 (0.72) | FLT3KITIRAK4AURKAJAK2 | |
| SCHEMBL12845289 | 0.85 | FLT3 (0.78) | FLT3KITIRAK4AURKAJAK2 | |
| SCHEMBL4040889 | 0.85 | FLT3 (0.78) | FLT3KITIRAK4AURKAJAK2 | |
| SCHEMBL4040253 | 0.84 | FLT3 (0.59) | FLT3KITIRAK4AURKAJAK2 | |
| SCHEMBL4036717 | 0.84 | FLT3 (0.76) | FLT3KITIRAK4AURKAJAK2 | |
| SCHEMBL4036435 | 0.83 | FLT3 (0.79) | FLT3KITIRAK4AURKAJAK2 | |
| SCHEMBL13963720 | 0.83 | FLT3 (0.72) | FLT3KITIRAK4AURKAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1562589-A2 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040214817-A1 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-28 | — | — | US | disclosed |
| WO-2004046120-A2 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | FLT3 220/4885KIT 1144/4885IRAK4 566/4885 |
| US-20040214817-A1 | Diaminotriazoles useful as inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K5 | FLT3 220/4885KIT 1144/4885IRAK4 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.